- Home
- HITI vs ABOS Comparison
HITI vs ABOS Comparison
Compare HITI & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HITI | ABOS |
|---|---|---|
| Founded | 2009 | 1996 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.8M | 197.9M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HITI | ABOS |
|---|---|---|
| Price | $2.31 | $2.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $6.13 | ★ $8.00 |
| AVG Volume (30 Days) | 315.1K | ★ 345.4K |
| Earning Date | 06-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.73 | N/A |
| Revenue Next Year | $12.80 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.02 | $1.19 |
| 52 Week High | $4.06 | $3.60 |
Technical Indicators
Market Signals| Indicator | HITI | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 58.10 | 49.19 |
| Support Level | $2.20 | $2.13 |
| Resistance Level | $2.60 | $2.43 |
| Average True Range (ATR) | 0.08 | 0.12 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 68.35 | 62.71 |
Price Performance
Historical ComparisonAbout HITI High Tide Inc.
High Tide Inc is a downstream-focused retailer of cannabis products, distributor, and seller of smoking accessories and cannabis lifestyle products. It is a vertically integrated company in the Canadian cannabis market with various brands in its portfolio such as Canna Cabana, Fastendr, Queen of Bud, Grasscity, Daily High Club, and others. The company's reportable operating segments are: Bricks and mortar, which generates maximum revenue, and E-commerce. Geographically, it derives maximum revenue from its business in Canada, followed by the United States of America, and other international markets.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.